pre-IPO PHARMA

COMPANY OVERVIEW

amcure leverages its exceptional knowledge of CD44 target biology to develop a pipeline of innovative therapeutic programs. In cancer, blocking the extracellular target CD44v6 could have a beneficial impact on several relevant receptor tyrosine kinase pathways.


LOCATION

  • Eggenstein-Leopoldshafen, , Germany

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://amcure.com/


    CAREER WEBSITE

    https://amcure.com/careers


    SOCIAL MEDIA


    INVESTORS

    biom-ag karlsruhe-institute-technology kfw-banking-group kg lbbw-venture-capital mbg-mittelstaendische-beteiligungsgesellschaft-baden-wuerttemberg s-kap-beteiligungen-pforzheim


    PRESS RELEASES


    Oct 22, 2018

    amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress


    Aug 6, 2018

    amcure Announces First Patient Dosed with AMC303 in Phase Ib Extension Cohort Based on Positive Safety Results


    Apr 17, 2018

    amcure Presents Pre-Clinical Anti-tumor and Anti-Metastatic Effects of AMC303 at AACR


    Jan 15, 2018

    amcure Appoints Biotech Executive Heinz Schwer to its Board


    Sep 11, 2017

    amcure Presents Phase I/Ib Study Design for Lead Compound AMC303 at ESMO 2017 Congress


    For More Press Releases


    Google Analytics Alternative